ASCENDIS PHARMA A/S -

Ascendis Pharma Receives Positive CHMP Opinion for TransCon™ PTH (palopegteriparatide) for Adults with Chronic Hypoparathyroidism

14 Sep 2023 11:22:57 By Nasdaq GlobeNewswire

Ascendis Pharma Reports Second Quarter 2023 Financial Results

05 Sep 2023 15:03:00 By Nasdaq GlobeNewswire

New Post Hoc Analysis Showed Substantial Improvement in Observed Estimated Glomerular Filtration Rate (eGFR), in TransCon PTH-Treated Adults with Hypoparathyroidism

05 Sep 2023 15:01:00 By Nasdaq GlobeNewswire

Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement

05 Sep 2023 15:01:00 By Nasdaq GlobeNewswire

Ascendis Pharma A/S Announces Three Upcoming Investor Presentations

24 Aug 2023 07:30:00 By Nasdaq GlobeNewswire

Ascendis Pharma to Report Second Quarter 2023 Financial Results and Provide Business Update on September 5, 2023

15 Aug 2023 07:30:00 By Nasdaq GlobeNewswire

One-Year Data from Phase 3 Trial of TransCon™ PTH in Adults with Hypoparathyroidism Presented at ENDO 2023

17 Jun 2023 16:30:00 By Nasdaq GlobeNewswire

Ascendis Pharma Showcases Its Latest Endocrinology Programs, Data, and Research at ENDO 2023

13 Jun 2023 08:21:55 By Nasdaq GlobeNewswire

Ascendis Pharma to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference

07 Jun 2023 07:30:00 By Nasdaq GlobeNewswire

Ascendis Pharma Opens Compassionate Use Program for TransCon™ PTH (palopegteriparatide) in Germany

05 Jun 2023 16:30:09 By Nasdaq GlobeNewswire

Ascendis Pharma Oncology Program Update Highlights Latest Clinical Data for Product Candidates

31 May 2023 07:30:00 By Nasdaq GlobeNewswire

Ascendis Pharma to Host Oncology Program Update on May 31

25 May 2023 07:30:00 By Nasdaq GlobeNewswire

Ascendis Pharma Showcases Commitment to Rare Endocrine Diseases at the 25th European Congress of Endocrinology 2023

13 May 2023 18:00:00 By Nasdaq GlobeNewswire

Ascendis Pharma to Participate in the BofA Securities 2023 Health Care Conference

03 May 2023 15:15:00 By Nasdaq GlobeNewswire

U.S. Food & Drug Administration Issues Complete Response Letter for TransCon™ PTH in Hypoparathyroidism

01 May 2023 06:00:00 By Nasdaq GlobeNewswire

Ascendis Pharma Reports First Quarter 2023 Financial Results

27 Apr 2023 15:01:00 By Nasdaq GlobeNewswire

Ascendis Pharma Announces First Quarter 2023 Financial Results and Business Update Conference Call on April 27

13 Apr 2023 07:30:00 By Nasdaq GlobeNewswire

Ascendis Pharma’s Initial Dose Escalation Results from the Ongoing Phase 1/2 Trial of TransCon™ IL-2 β/γ Accepted for Online Publication at ASCO 2023

03 Apr 2023 06:05:00 By Nasdaq GlobeNewswire

Ascendis Pharma Provides Update on Regulatory Reviews of TransCon PTH™ in Hypoparathyroidism

03 Apr 2023 06:00:00 By Nasdaq GlobeNewswire

Ascendis Pharma to Participate in the Oppenheimer 33rd Annual Healthcare Conference

10 Mar 2023 07:00:00 By Nasdaq GlobeNewswire